Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

4期 已完成 NCT03061006

摘要

Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study. After written informed consent is obtained, subjects who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: Group 1: Dabigatran etexilate (150 mg BID if CrCL \> 30 mL/min, or 75 mg BID if CrCL \> 15 to 30 mL/min or per USPI; and Group 2: Warfarin (Dose-adjusted (INR 2.0 - 3.0). Assessment of kidney function every 6 months will be done for Group 1. Standard warfarin follow-up and education, based upon system criteria, will be done for Group 2. All subjects will be followed for 24 months, and will be assessed at 1-week, then 3-, 6-, 12-, 18- and 24-months post-anticoagulation visits as well as other visits deem necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit following the week 1 visit, except at the 3-month visit when only one questionnaire will be administered. To determine brain volume and characteristic changes representative

Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist

24 months · Participants

Number of Participants With Moderate Decline in Cognitive Function Based on Results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia.

24 months · Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
• Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
• Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation — Massachusetts General Hospital
• Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintai — Ottawa Heart Institute Research Corporation

全部试验